Positive results show that the average weight loss was 12.5 kg (11.8% body weight reduction) with cagrilintide compared to 2.5 kg (2.3%) with placebo, after 68 weeks *1 ,2 Cagrilintide was well-tolerated, with the most common side effects being gastrointestinal
Stop and Seek Help If Severe allergic reaction (rash, swelling, difficulty breathing) Persistent severe nausea or vomiting not improving with dose reduction Signs of pancreatitis (severe abdominal pain radiating to back) Planned pregnancy or positive pregnancy test Inability to maintain adequate nutrition despite dose adjustments Any concerning symptoms your healthcare provider advises stopping for Always consult your healthcare provider before stopping or modifying your dose
AOD-9604 is generally well-tolerated with a favorable safety profile based on clinical research involving approximately 900 participants across six studies
These and additional studies led the US Environmental Protection Agency (EPA) to classify radon as a carcinogen owing to its causal association with lung cancer, and both the EPA and the National Radon Safety Board advocate radon screening and mitigation in homes across the USA 240,241
Testing during this window often returns false-negative results
In addition, new drugs such as tirzepatide have come onto the market, expanding the therapeutic options for successful treatment of T2DM and obesity
